Compare · DXCM vs STVN
DXCM vs STVN
Side-by-side comparison of DexCom Inc. (DXCM) and Stevanato Group S.p.A. (STVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and STVN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 5.4x STVN ($5.45B).
- Over the past year, DXCM is down 10.6% and STVN is down 22.8% - DXCM leads by 12.2 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 5 for STVN).
- DXCM has more recent analyst coverage (25 ratings vs 21 for STVN).
- Company
- DexCom Inc.
- Stevanato Group S.p.A.
- Price
- $76.59+5.15%
- $18.00-2.81%
- Market cap
- $29.57B
- $5.45B
- 1M return
- +25.71%
- -0.08%
- 1Y return
- -10.56%
- -22.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2021
- News (4w)
- 26
- 5
- Recent ratings
- 25
- 21
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest STVN
- Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
- SEC Form 6-K filed by Stevanato Group S.p.A.
- Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting
- Wolfe Research resumed coverage on Stevanato Group S.p.A. with a new price target
- SEC Form SD filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.